Dupixent Commercial - Search News

sBLA, Dupixent and bullous pemphigoid

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.

Business Insider · 1d

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority

The Pharma Letter · 1d

FDA accepts Dupixent sBLA for priority review in bullous pemphigoid

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

FiercePharma12d

Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

BioSpace15d

Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

FierceBiotech12d

Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

pharmaphorum6y

FDA to review Sanofi's Dupixent in asthma

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results